Frontier Capital Management’s Apogee Therapeutics APGE Stock Holding History

Frontier Capital Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.3M	Sell	303,739 -760,744	-71%	-$68.5M	0.38%	97
2026 Q1	$89.6M	Buy	1,064,483 +584,030	+122%	+$42.4M	0.92%	19
2025 Q4	$36.3M	Buy	480,453 +106,046	+28%	+$6.68M	0.38%	86
2025 Q3	$14.9M	Buy	374,407 +65,341	+21%	+$2.49M	0.13%	214
2025 Q2	$13.4M	Buy	309,066 +200,249	+184%	+$7.62M	0.12%	217
2025 Q1	$4.07M	Sell	108,817 -63,894	-37%	-$2.47M	0.04%	260
2024 Q4	$7.82M	Sell	172,711 -138,605	-45%	-$7.07M	0.07%	235
2024 Q3	$18.3M	Buy	+311,316	New	+$14.9M	0.17%	177
2024 Q2	–	Sell	-76,481	Closed	-$5.08M	–	281
2024 Q1	$5.08M	Buy	+76,481	New	+$3.34M	0.05%	246

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Frontier Capital Management's APGE Position: Q2 2026 in Review

Frontier Capital Management reduced its Apogee Therapeutics (APGE) stake by 71% in Q2 2026, selling an estimated $68.5M and leaving 303,739 shares worth $40.3M. The position accounts for 0.38% of the portfolio, ranked #97.

Frontier Capital Management first reported a position in APGE in Q1 2024 and has held it in 9 quarters since. The position peaked at $89.6M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Frontier Capital Management held 303,739 shares of Apogee Therapeutics worth $40.3M as of Q2 2026.
Frontier Capital Management sold 760,744 Apogee Therapeutics shares in Q2 2026, an estimated $68.5M.
Apogee Therapeutics made up 0.38% of Frontier Capital Management's portfolio in Q2 2026, its #97 holding.
Frontier Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 9 quarters since.
Frontier Capital Management's Apogee Therapeutics position peaked at $89.6M in Q1 2026.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.